Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.89B
Close$
$62.99
79.4% downside
Current Fair Value
79.4% downsideOvervalued by 79.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.89 Billion |
|---|---|
| Enterprise Value | $5.66 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $6.44 |
| Beta | 1.01 |
| Outstanding Shares | 20,063,000 |
Return
| Return on Equity | 19.07% |
|---|---|
| Return on Assets | 8.44% |
| Return on Invested Capital | 10.27% |
Valuation & Multiples
| P/E Ratio | 29.52 |
|---|---|
| PEG | 3.28 |
| Price to Sales | 21.89 |
| Price to Book Ratio | 6.38 |
| Enterprise Value to Revenue | 19.48 |
| Enterprise Value to EBIT | 25.75 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$2.00
Average shareholder expectationRevenue Estimate
$63.99 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$2.33
Average shareholder expectationRevenue Estimate
$77.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 85.43% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.41%▼ 107.33% |
|---|---|
| Total Invested | $401.39M▼ 94.43% |
| Investors Holding | 36▼ 394.00% |
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
47 employees
CEO: John Higgins Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its...